Human Chorionic Gonadotropin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Human Chorionic Gonadotropin Market Analysis

Over the next few years, the human chorionic gonadotropin market is expected to register a CAGR of about 7.6%.

Due to COVID-19 restrictions worldwide, foot traffic in hospitals and clinics decreased significantly, negatively impacting the growth of the human chorionic gonadotropin market. For instance, according to the research study published by Frontiers Media S.A. in April 2022, many infertile patients decided not to request assisted reproductive technology (ART) treatments due to the pandemic. During the pandemic, there was a decline in the number of concluded ART cycles as compared to the preceding year (749 vs. 844 cycles). This decline, despite the unchanged availability of ART services, is attributed to many factors: the local restrictions and the fear of SARS-Cov-2 infection and potential adverse obstetric outcomes did not encourage physicians and patients to engage in ART. Although, with the ongoing vaccinations and decreasing cases of COVID-19, the market is expected to regain normalcy over the coming years.

The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman's chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.

In addition, increasing awareness about HCG among healthcare professionals and patients, coupled with the new product launches, is anticipated to boost the market's growth over the forecast period. Human chorionic gonadotropin is used as a marker in cancer, including choriocarcinoma, seminoma, and germ cell tumors, which may augment the market's growth over the coming years with the increasing cases of cancer. For example, as per the article published in January 2020 by David G. Grenache, HCG was initially developed as a test for pregnancy. But HCG is now commonly used to test women who might have an ectopic pregnancy, along with other biomarkers, to look for fetal aneuploidies and as a tumor marker for a wide range of neoplasms.

Therefore, the factors mentioned above are attributed collectively to the studied market's growth over the forecast period. However, the availability of substitutes is expected to hinder market growth over the forecast period.

Human Chorionic Gonadotropin Market Trends

This section covers the major market trends shaping the Human Chorionic Gonadotropin Market according to our research experts:

Female Infertility Treatment Segment is Anticipated to Grow at a Significant Rate Over the Forecast Period

Human Chorionic Gonadotropin Industry Segmentation

As per the scope of the report, the human chorionic gonadotropin hormone is a placental hormone secreted by syncytiotrophoblast cells during pregnancy. These hormones stimulate the corpus luteum to produce progesterone. The naturally extracted or recombinant human chorionic gonadotropin hormones are used in the treatment of infertility, male hypogonadism, and many other conditions. The human chorionic gonadotropin market is segmented by product (naturally extracted and recombinant), application (male hypogonadism, female infertility treatment, oligospermia treatment, and other applications), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.